Race Oncology Receives Ethics Committee's Nod for Phase 1 Trial of Cancer Treatment Drug Candidate; Shares Rise 9%

MT Newswires Live

Mar 14, 2025

Race Oncology (ASX:RAC) said that the Bellberry Human Research Ethics Committee approved its phase 1 trial of its reformulated bisantrene drug candidate RC220, in combination with doxorubicin for patients with solid tumors, according to a Friday filing with the Australian bourse.

The open-label, multi-center trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of the drug candidate as a standalone treatment and in combination with doxorubicin.

It will start at Southside Cancer Care Centre in New South Wales this month, pending institutional approval, with up to nine additional sites to follow, the filing said.

Stage 1 of the trial involves dose escalation to determine the maximum tolerated combined dose (MTCD) in up to 33 patients, the filing added.

Stage 2 will expand to patients who haven't received anthracyclines, confirming safety and exploring endpoints like cardioprotection and anticancer effects, the company said.

Shares of the company rose 9% in recent Friday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2519899968"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2519899968\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2519899968?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-14 08:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2519899968","market":"fut","top_or_hot":-1,"title":"Race Oncology Receives Ethics Committee's Nod for Phase 1 Trial of Cancer Treatment Drug Candidate; Shares Rise 9%","media":"MT Newswires Live","content":"<html><body><p> Race Oncology (ASX:RAC) said that the Bellberry Human Research Ethics Committee approved its phase 1 trial of its reformulated bisantrene drug candidate RC220, in combination with doxorubicin for patients with solid tumors, according to a Friday filing with the Australian bourse.</p><p>The open-label, multi-center trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of the drug candidate as a standalone treatment and in combination with doxorubicin.</p><p>It will start at Southside Cancer Care Centre in New South Wales this month, pending institutional approval, with up to nine additional sites to follow, the filing said.</p><p>Stage 1 of the trial involves dose escalation to determine the maximum tolerated combined dose (MTCD) in up to 33 patients, the filing added.</p><p>Stage 2 will expand to patients who haven't received anthracyclines, confirming safety and exploring endpoints like cardioprotection and anticancer effects, the company said.</p><p>Shares of the company rose 9% in recent Friday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Race Oncology Receives Ethics Committee's Nod for Phase 1 Trial of Cancer Treatment Drug Candidate; Shares Rise 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRace Oncology Receives Ethics Committee's Nod for Phase 1 Trial of Cancer Treatment Drug Candidate; Shares Rise 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-14 08:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Race Oncology (ASX:RAC) said that the Bellberry Human Research Ethics Committee approved its phase 1 trial of its reformulated bisantrene drug candidate RC220, in combination with doxorubicin for patients with solid tumors, according to a Friday filing with the Australian bourse.</p><p>The open-label, multi-center trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of the drug candidate as a standalone treatment and in combination with doxorubicin.</p><p>It will start at Southside Cancer Care Centre in New South Wales this month, pending institutional approval, with up to nine additional sites to follow, the filing said.</p><p>Stage 1 of the trial involves dose escalation to determine the maximum tolerated combined dose (MTCD) in up to 33 patients, the filing added.</p><p>Stage 2 will expand to patients who haven't received anthracyclines, confirming safety and exploring endpoints like cardioprotection and anticancer effects, the company said.</p><p>Shares of the company rose 9% in recent Friday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2519899968","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519899968","pubTimestamp":1741910491,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Race Oncology  said that the Bellberry Human Research Ethics Committee approved its phase 1 trial of its reformulated bisantrene drug candidate RC220, in combination with doxorubicin for patients with solid tumors, according to a Friday filing with the Australian bourse.The open-label, multi-center trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of the drug candidate as a standalone treatment and in combination with doxorubicin.It will start at Southside Cancer Care Centre in New South Wales this month, pending institutional approval, with up to nine additional sites to follow, the filing said.Stage 1 of the trial involves dose escalation to determine the maximum tolerated combined dose  in up to 33 patients, the filing added.Stage 2 will expand to patients who haven't received anthracyclines, confirming safety and exploring endpoints like cardioprotection and anticancer effects, the company said.Shares of the company rose 9% in recent Friday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","RAC.AU":"RACE ONCOLOGY LTD","BK7508":"医药生物股"},"translate_title":"Race Oncology获得伦理委员会对癌症治疗候选药物1期试验的认可；股价上涨9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":0.9},"content_text":"Race Oncology (ASX:RAC) said that the Bellberry Human Research Ethics Committee approved its phase 1 trial of its reformulated bisantrene drug candidate RC220, in combination with doxorubicin for patients with solid tumors, according to a Friday filing with the Australian bourse.The open-label, multi-center trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of the drug candidate as a standalone treatment and in combination with doxorubicin.It will start at Southside Cancer Care Centre in New South Wales this month, pending institutional approval, with up to nine additional sites to follow, the filing said.Stage 1 of the trial involves dose escalation to determine the maximum tolerated combined dose (MTCD) in up to 33 patients, the filing added.Stage 2 will expand to patients who haven't received anthracyclines, confirming safety and exploring endpoints like cardioprotection and anticancer effects, the company said.Shares of the company rose 9% in recent Friday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}